Literature DB >> 35673912

[Characteristics of N6-methyladenosine modification patterns in t(8;21) acute myeloid leukemia].

Y Wen1,2, S Fang2,3, J Yang1,2, H Wang1,2, Y Jiao1,2, N Wang1,2, Y Wei1,2, L Wang2, L Dou2.   

Abstract

OBJECTIVE: To investigate the relationship between AML1-ETO (AE) fusion gene and intracellular N6-methyladenosine (m6A) modification pattern in t(8;21) acute myeloid leukemia (AML).
METHODS: RNA m6A sequencing was performed in SKNO-1 and AE knockdown SKNO-1 (SKNO-1 siAE) cells using RNA-protein co-immunoprecipitation and high-throughput sequencing (methylated RNA immunoprecipitation sequencing, MeRIP-Seq) to analyze the changes in m6A modification of the entire transcriptome. Transcriptome sequencing (RNA-seq) was performed using high-throughput sequencing. The differentially modified mRNAs were further functionally annotated by Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The changes in m6A-related enzyme expressions were detected using real-time PCR.
RESULTS: A total of 26 441 genes were identified in AE knockdown AML cells and AE-expressing cells, containing 72 036 m6A peaks. AE knockdown caused a reduction of the number of intracellular m6A peaks from 37 042 to 34 994, among which 1278 m6A peaks were significantly elevated and 1225 were significantly decreased; 1316 genes with newly emerged m6A modification were detected and 1830 genes lost m6A modification after AE knockdown. The differential peaks were mainly enriched in pathways involving cancer and human T-lymphocytic leukemia virus I. RNA-seq results showed that 2483 genes were up-regulated and 3913 genes were down-regulated after AE knockdown. The combined analysis of MeRIP-Seq and RNA-Seq results revealed relatively high expression levels of m6A-modified genes as compared with the genes without m6A modification (SKNO-1: 0.6116±1.263 vs 2.010±1.655, P < 0.0001; SKNO-1 siAE: 0.5528±1.257 vs 2.067±1.686, P < 0.0001). The m6A modified genes located in the 3'UTR or 5 'UTR had significantly higher expression levels than those located in exonic regions (SKNO-1: 2.177± 1.633 vs 1.333 ± 1.470 vs 2.449 ± 1.651, P < 0.0001; SKNO-1 siAE: 2.304 ± 1.671 vs 1.336 ± 1.522 vs 2.394 ± 1.649, P < 0.05). Analysis of RNA-seq data identified 3 m6A-related enzymes that showed significantly elevated mRNA expression after AE knockdown, namely WTAP, METTL14, and ALKBH5 (P < 0.05), but the results of real-time PCR showed that the expressions of WTAP and ALKBH5 were significantly increased while the expression of METTL14 was lowered after AE knockdown (P < 0.05).
CONCLUSION: AE knockdown results in differential expressions of m6A-associated enzymes, suggesting that the AE fusion gene regulates the expression of one or more m6A-associated enzymes to control cellular methylation levels.

Entities:  

Keywords:  AML1-ETO; N6-methyladenosine; acute myeloid leukemia

Mesh:

Substances:

Year:  2022        PMID: 35673912      PMCID: PMC9178644          DOI: 10.12122/j.issn.1673-4254.2022.05.09

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  37 in total

Review 1.  Gene expression regulation mediated through reversible m⁶A RNA methylation.

Authors:  Ye Fu; Dan Dominissini; Gideon Rechavi; Chuan He
Journal:  Nat Rev Genet       Date:  2014-03-25       Impact factor: 53.242

2.  Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons.

Authors:  Kate D Meyer; Yogesh Saletore; Paul Zumbo; Olivier Elemento; Christopher E Mason; Samie R Jaffrey
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

Review 3.  TNF-R1 signaling: a beautiful pathway.

Authors:  Guoqing Chen; David V Goeddel
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

4.  Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide.

Authors:  C Sakakura; Y Yamaguchi-Iwai; M Satake; S C Bae; A Takahashi; E Ogawa; A Hagiwara; T Takahashi; A Murakami; K Makino
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

Review 5.  Transcriptional dysregulation during myeloid transformation in AML.

Authors:  T Pabst; B U Mueller
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

6.  A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation.

Authors:  Jianzhao Liu; Yanan Yue; Dali Han; Xiao Wang; Ye Fu; Liang Zhang; Guifang Jia; Miao Yu; Zhike Lu; Xin Deng; Qing Dai; Weizhong Chen; Chuan He
Journal:  Nat Chem Biol       Date:  2013-12-06       Impact factor: 15.040

7.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase.

Authors:  Xiao-Li Ping; Bao-Fa Sun; Lu Wang; Wen Xiao; Xin Yang; Wen-Jia Wang; Samir Adhikari; Yue Shi; Ying Lv; Yu-Sheng Chen; Xu Zhao; Ang Li; Ying Yang; Ujwal Dahal; Xiao-Min Lou; Xi Liu; Jun Huang; Wei-Ping Yuan; Xiao-Fan Zhu; Tao Cheng; Yong-Liang Zhao; Xinquan Wang; Jannie M Rendtlew Danielsen; Feng Liu; Yun-Gui Yang
Journal:  Cell Res       Date:  2014-01-10       Impact factor: 25.617

8.  RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.

Authors:  Anetta Ptasinska; Anna Pickin; Salam A Assi; Paulynn Suyin Chin; Luke Ames; Roberto Avellino; Stefan Gröschel; Ruud Delwel; Peter N Cockerill; Cameron S Osborne; Constanze Bonifer
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

9.  A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.

Authors:  Xiao-Jian Sun; Zhanxin Wang; Lan Wang; Yanwen Jiang; Nils Kost; T David Soong; Wei-Yi Chen; Zhanyun Tang; Tomoyoshi Nakadai; Olivier Elemento; Wolfgang Fischle; Ari Melnick; Dinshaw J Patel; Stephen D Nimer; Robert G Roeder
Journal:  Nature       Date:  2013-06-30       Impact factor: 49.962

10.  Editorial Special Issue TGF-beta/BMP Signaling Pathway.

Authors:  Isabel Fabregat; Blanca Herrera; Aránzazu Sánchez
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.